TP53 and neoplasm: However, it still remained challenging to design stapled PMI peptides that efficiently inhibit p53-dependent tumor growth in cell culture and, more importantly, in vivo, due in part to the rapid accumulation of both MDM2 and MDMX in cancer cells.